Is Immix Biopharma, Inc. (IMMX) a Buy, Sell, or Hold?
Immix Biopharma, Inc.
NASDAQ:IMMX
$10.53 USD
-$0.15 (-1.4%)
- Volume
- 967.88K
- Average Volume
- 1.55M
- Market Capitalization
- $572.85M
- P/E Ratio
- -11.45
- Dividend Yield
- 0.00%
- Price Target
- $17.00
- Year High
- $12.14
- Year Low
- $1.94
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.76
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Ilya Rachman |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IMMX |
| CUSIP | 45258H106 |
| CIK | 0001873835 |
| Web | https://www.immixbio.com |
| Phone | 310 651 8041 |
| Currency | USD |
| Employees | 21 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.76 |
| Quick Ratio | 8.76 |
| Cash Ratio | 7.52 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -0.86 |
| Price / Cash Flow | -17.48 |
| Price / Book | 4.78 |
Price Target and Rating
| Average Stock Price Forecast | $17.00 |
| High Stock Price Forecast | $20.00 |
| Low Stock Price Forecast | $14.00 |
| Forecast Upside/Downside | -38.06% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 4 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.89 |
| Trailing P/E Ratio | -11.45 |
| PEG Ratio | 0.45 |
| P/E Growth | 0.45 |
| Net Income | -$29.44M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -73.23% |
| Return on Assets | -36.51% |
Financials Score
| AltmanZ Score | 28.16 |
| Piotroski Score | 2.00 |
| Working Capital | 81.74M |
| Total Assets | 95.82M |
| Ebit | -34.95M |
| Market Cap | 572.85M |
| Total Liabilities | 11.45M |
Poll Results
About Immix Biopharma, Inc. (NASDAQ:IMMX) Stock
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating ... IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy
2026-06-24 13:01:07
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
2026-06-18 13:38:04
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.
2026-06-18 10:55:17
The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2026-05-27 10:55:16
The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
2026-05-22 17:15:00
- Financing includes leading U. S. biotechnology institutional investors and mutual funds - LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
2026-05-22 17:15:00
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $140.65 million.
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
2026-05-21 06:30:00
LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $150 million. The offering is expected to close on or about May 22, 2026, subject to the satisfaction of customary closing conditions.
2026-05-21 06:00:00
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No relapses to-date observed for patients who have reached CR – – All subsequently enrolled patients for whom MRD results are available are MRD-negative at one month – – Next NEXICART-2 Update Expected Late September, 2026 – LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted to complete response (CR). The NEXICART-2 CR rate is now 95% (19 out of 20 patients).
Frequently Asked Questions
-
What is the current Immix Biopharma, Inc. (IMMX) stock price?
-
Immix Biopharma, Inc.(NASDAQ:IMMX) stock price is $10.53 in the last trading session. During the trading session, IMMX stock reached the peak price of $12.14 while $1.94 was the lowest point it dropped to. The percentage change in IMMX stock occurred in the recent session was --1.4% while the dollar amount for the price change in IMMX stock was -$0.15.
-
IMMX's industry and sector of operation?
-
The NASDAQ listed IMMX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IMMX?
-
Ilya Rachman | Co-Founder, CEO, Chief Scientific Officer & Chairman
Gabriel Morris | President, CFO & Director
Vladimir Torchilin | Scientific Co-Founder
David Marks | Chief Medical Officer of Cell Therapy
Graham Ross FFPM | Chief Medical Officer & Head of Clinical Development -
How many employees does IMMX have?
-
Number of IMMX employees currently stands at 21. IMMX operates from 11400 West Olympic Boulevard, Los Angeles, CA 90064, US.
-
Link for IMMX official website?
-
Official Website of IMMX is: https://www.immixbio.com
-
How do I contact IMMX?
-
IMMX could be contacted at phone #310 651 8041 and can also be accessed through its website. IMMX operates from 11400 West Olympic Boulevard, Los Angeles, CA 90064, US.
-
How many shares of IMMX are traded daily?
-
The average number of IMMX shares traded daily for last 3 months was 1.55M.
-
What is the market cap of IMMX currently?
-
The market value of IMMX currently stands at $572.85M with its latest stock price at $10.53